Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice

Journal of Endocrinology

Volumn 223, Issue 1, 2014, Pages 25-33

  Saidak, Zuzana ^a,b   Henaff, Carole Le ^a,b   Azzi, Sofia ^a,b   Marty, Caroline ^a,b   Marie, Pierre J ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Low dose PTH; Osteoblast activity; Senescent mice; Wnt signalling

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; N TERMINAL PROPEPTIDE TYPE 1 PROCOLLAGEN; PARATHYROID HORMONE[1-34]; SCLEROSTIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MEF2C; UNCLASSIFIED DRUG; WISP1 PROTEIN; WNT PROTEIN; CCN PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; GLYCOPROTEIN; MEF2C PROTEIN, MOUSE; MYOCYTE ENHANCER FACTOR 2; ONCOPROTEIN; PARATHYROID HORMONE; SOST PROTEIN, MOUSE; WISP1 PROTEIN, MOUSE;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW STROMA CELL; BONE MASS; CELL FUNCTION; CELL MATURATION; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; LOW DRUG DOSE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOPENIA; PROTEIN EXPRESSION; SENESCENCE ACCELERATED MOUSE; TRABECULAR BONE; TREATMENT DURATION; AGING; ANIMAL; BLOOD; BONE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLIC BONE DISEASE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY;

AGING; ANIMALS; BONE AND BONES; BONE DISEASES, METABOLIC; CCN INTERCELLULAR SIGNALING PROTEINS; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GLYCOPROTEINS; MEF2 TRANSCRIPTION FACTORS; MICE; OSTEOBLASTS; OSTEOCYTES; PARATHYROID HORMONE; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY; X-RAY MICROTOMOGRAPHY;

EID: 84907863539     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0249     Document Type: Article

References (50)

1. Andrews SF, Dai X, Ryu BY, Gulick T, Ramachandran B&Rawlings DJ 2012 Developmentally regulated expression of MEF2C limits the response to BCR engagement in transitional B cells. European Journal of Immunology 42 1327-1336. (doi:10.1002/eji.201142226)
2. Baron R&Kneissel M 2013 WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nature Medicine 19 179-192. (doi:10.1038/nm.3074)
3. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC & Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146 4577-4583. (doi:10.1210/en.2005-0239)
4. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P&Lowik CW 2004 Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. Journal of Experimental Medicine 199 805-814. (doi:10.1084/jem.20031454)
5. Bodine PV&Komm BS 2006 Wnt signaling and osteoblastogenesis. Reviews in Endocrine&Metabolic Disorders 7 33-39. (doi:10.1007/s11154-006-9002-4)
6. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB&Komm BS 2004 The Wnt antagonist secreted Frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Molecular Endocrinology 18 1222-1237. (doi:10.1210/me.2003-0498)
7. Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ&Komm BS 2007 Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted Frizzled-related protein-1. Journal of Cellular Physiology 210 352-357. (doi:10.1002/jcp.20834)
8. Bonnet N, Conway SJ&Ferrari SL 2012 Regulation of ß catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. PNAS 109 15048-15053. (doi:10.1073/pnas.1203085109)
9. Bovolenta P, Esteve P, Ruiz JM, Cisneros E&Lopez-Rios J 2008 Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. Journal of Cell Science 121 737-746. (doi:10.1242/jcs.026096)
10. Brennan TC, Rizzoli R&Ammann P 2009 Selective modification of bone quality by PTH, pamidronate, or raloxifene. Journal of Bone and Mineral Research 24 800-808. (doi:10.1359/jbmr.081227)
11. Canalis E, Centrella M, Burch W&McCarthy TL 1989 Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. Journal of Clinical Investigation 83 60-65. (doi:10.1172/JCI113885)
12. Canalis E, Giustina A&Bilezikian JP 2007 Mechanisms of anabolic therapies for osteoporosis. New England Journal of Medicine 357 905-916. (doi:10.1056/NEJMra067395)
13. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR&Varmus HE 2005 FGF-20 and DKK1 are transcriptional targets of ß-catenin and FGF-20 is implicated in cancer and development. EMBO Journal 24 73-84. (doi:10.1038/sj.emboj.7600460)
14. Clement-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssiere B, Belleville C, Estrera K, Warman ML, Baron R&Rawadi G 2005 Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. PNAS 102 17406-17411. (doi:10.1073/pnas.0505259102)
15. Clevers H 2006 Wnt/ß-catenin signaling in development and disease. Cell 127 469-480. (doi:10.1016/j.cell.2006.10.018)
16. Collette NM, Genetos DC, Economides AN, Xie L, Shahnazari M, Yao W, Lane NE, Harland RM&Loots GG 2012 Targeted deletion of Sost distal enhancer increases bone formation and bone mass. PNAS 109 14092-14097. (doi:10.1073/pnas.1207188109)
17. Compston JE 2007 Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40 1447-1452. (doi:10.1016/j.bone.2006.09.008)
18. Fei Y, Gronowicz G&Hurley MM 2013 Fibroblast growth factor-2, bone homeostasis and fracture repair. Current Pharmaceutical Design 19 3354-3363. (doi:10.2174/1381612811319190002)
19. French DM, Kaul RJ, D'Souza AL, Crowley CW, Bao M, Frantz GD, Filvaroff EH & Desnoyers L 2004 WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. American Journal of Pathology 165 855-867. (doi:10.1016/S0002-9440(10)63348-2)
20. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS et al. 2005 Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. Journal of Biological Chemistry 280 33132-33140. (doi:10.1074/jbc.M500608200)
21. Gordon MD&Nusse R 2006 Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. Journal of Biological Chemistry 281 22429-22433. (doi:10.1074/jbc.R600015200)
22. Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJ, Kuhstoss SA, Thomas CC, Schipani E, Baron R et al. 2010 Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metabolism 11 161-171. (doi:10.1016/j.cmet.2009.12.007)
23. 2-adrenergic receptor. PNAS 109 7433-7438. (doi:10.1073/pnas.1109036109)
24. Haÿ E, Laplantine E, Geoffroy V, Frain M, Kohler T, Muller R&Marie PJ 2009 N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/ß-catenin signaling, osteoblast function, and bone formation. Molecular and Cellular Biology 29 953-964. (doi:10.1128/MCB.00349-08)
25. Jilka RL 2007 Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40 1434-1446. (doi:10.1016/j.bone.2007.03.017)
26. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM&Manolagas SC 1996 Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. Journal of Clinical Investigation 97 1732-1740. (doi:10.1172/JCI118600)
27. Jilka RL, Almeida M, Ambrogini E, Han L, Roberson PK, Weinstein RS & Manolagas SC 2010 Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell 9 851-867. (doi:10.1111/j.1474-9726.2010.00616.x)
28. Kassem M&Marie PJ 2011 Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell 10 191-197. (doi:10.1111/j.1474-9726.2011.00669.x)
29. Kawano Y&Kypta R 2003 Secreted antagonists of the Wnt signalling pathway. Journal of Cell Science 116 2627-2634. (doi:10.1242/jcs.00623)
30. Keller H&Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37 148-158. (doi:10.1016/j.bone.2005.03.018)
31. Khosla S, Bellido TM, Drezner MK, Gordon CM, Harris TB, Kiel DP, Kream BE, LeBoff MS, Lian JB, Peterson CA et al. 2011 Forum on aging and skeletal health: summary of the proceedings of an ASBMR workshop. Journal of Bone and Mineral Research 26 2565-2578. (doi:10.1002/jbmr.488)
32. Kim SW, Pajevic PD, Selig M, Barry KJ, Yang JY, Shin CS, Baek WY, Kim JE & Kronenberg HM 2012 Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. Journal of Bone and Mineral Research 27 2075-2084. (doi:10.1002/jbmr.1665)
33. Knopp E, Troiano N, Bouxsein M, Sun BH, Lostritto K, Gundberg C, Dziura J & Insogna K 2005 The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology 146 1983-1990. (doi:10.1210/en.2004-0770)
34. Kramer I, Loots GG, Studer A, Keller H&Kneissel M 2010 Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. Journal of Bone and Mineral Research 25 178-189. (doi:10.1359/jbmr.090730)
35. Kramer I, Baertschi S, Halleux C, Keller H&Kneissel M 2012 Mef2c deletion in osteocytes results in increased bone mass. Journal of Bone and Mineral Research 27 360-373. (doi:10.1002/jbmr.1492)
36. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT&Onyia JE 2005 Effects of parathyroid hormone on Wnt signaling pathway in bone. Journal of Cellular Biochemistry 95 1178-1190. (doi:10.1002/jcb.20506)
37. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M&Keller H 2007 Control of the SOST bone enhancer by PTH using MEF2 transcription factors. Journal of Bone and Mineral Research 22 1957-1967. (doi:10.1359/jbmr.070804)
38. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE&Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Journal of Biological Chemistry 280 19883-19887. (doi:10.1074/jbc.M413274200)
39. Manolagas SC&Parfitt AM 2010 What old means to bone. Trends in Endocrinology and Metabolism 21 369-374. (doi:10.1016/j.tem.2010.01.010)
40. Marie PJ 2014 Bone cell senescence: mechanisms and perspectives. Journal of Bone and Mineral Research 29 1311-1321. (doi:10.1002/jbmr.2190)
41. Ono M, Inkson CA, Kilts TM&Young MF 2011 WISP-1/CCN4 regulates osteogenesis by enhancing BMP-2 activity. Journal of Bone and Mineral Research 26 193-208. (doi:10.1002/jbmr.205)
42. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM&Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research 2 595-610. (doi:10.1002/jbmr.5650020617)
43. Qin L, Qiu P, Wang L, Li X, Swarthout JT, Soteropoulos P, Tolias P & Partridge NC 2003 Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. Journal of Biological Chemistry 278 19723-19731. (doi:10.1074/jbc.M212226200)
44. Rauner M, Sipos W&Pietschmann P 2008 Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation. Age 30 273-282. (doi:10.1007/s11357-008-9069-9)
45. Saidak Z, Haÿ E, Marty C, Barbara A&Marie PJ 2012 Strontium ranelate rebalances bone marrow adipogenesis and osteoblastogenesis in senescent osteopenic mice through NFATc/Maf and Wnt signaling. Aging Cell 11 467-474. (doi:10.1111/j.1474-9726.2012.00804.x)
46. Tobimatsu T, Kaji H, Sowa H, Naito J, Canaff L, Hendy GN, Sugimoto T & Chihara K 2006 Parathyroid hormone increases ß-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 147 2583-2590. (doi:10.1210/en.2005-1627)
47. Wan M, Yang C, Li J, Wu X, Yuan H, Ma H, He X, Nie S, Chang C&Cao X 2008 Parathyroid hormone signaling through low-density lipoproteinrelated protein 6. Genes and Development 22 2968-2979. (doi:10.1101/gad.1702708)
48. Xu L, Corcoran RB, Welsh JW, Pennica D&Levine AJ 2000 WISP-1 is a Wnt-1- and ß-catenin-responsive oncogene. Genes and Development 14 585-595. (doi:10.1101/gad.14.5.585)
49. Yao W, Cheng Z, Shahnazari M, Dai W, Johnson ML&Lane NE 2010 Overexpression of secreted Frizzled-related protein 1 inhibits bone formation and attenuates PTH bone anabolic effects. Journal of Bone and Mineral Research 25 190-199. (doi:10.1359/jbmr.090719)
50. Yao GQ, Wu JJ, Troiano N&Insogna K 2011 Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. Journal of Bone and Mineral Metabolism 29 141-148. (doi:10.1007/s00774-010-0202-3)